1 / 46

7 th July CRH talk

7 th July CRH talk. Dr George Hruby Senior Staff Specialist Sydney Cancer Centre. Outline of Talk. IGRT (Image Guided Radiation Treatment) as applied to prostate cancer Update the Sydney Cancer Centre HDR (high dose rate) brachytherapy programme. Introduction.

christen-alvarado
Télécharger la présentation

7 th July CRH talk

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 7th July CRH talk Dr George Hruby Senior Staff Specialist Sydney Cancer Centre

  2. Outline of Talk • IGRT (Image Guided Radiation Treatment) as applied to prostate cancer • Update the Sydney Cancer Centre HDR (high dose rate) brachytherapy programme

  3. Introduction Dose escalation confers significant disease control benefit in localised prostate cancer. 7 RCTs show 10-20% improvement in FFF with increased dose. Caveat… • EBRT – landmark MD Anderson trial – FFF 78% in 78Gy arm v 59% for 70Gy • HDR brachytherapy as a boost

  4. CT simulation

  5. CT sim

  6. Dual energy Linac with MLC

  7. Conformal Radiation treatment Up until recently, EBRT has relied on a single planning CT “snap-freeze” taken before treatment starts. Regular X-rays (port films) were performed to ensure the pelvic bony anatomy was in the same position But – required bigger margins to account for organ motion - Could not visualize the prostate itself or its relationship to OAR (organs at risk) eg rectum/bladder

  8. treatment

  9. EBRT

  10. Reducing target uncertainty • Rectal balloon • Flatus tubes Image Guidance • Trans-abdominal ultrasound (BAT) • Cone beam CT • Fiducial markers Brachytherapy

  11. Prostate: EBRT Fiducials • In house feasibility trial of fiducial markers 2007/8 • Ethics approved for 25 patients • 1st 5 patients – feasibility alone • Current 20 – daily “on line” localization • Feasibility study completed early 2008 • Standard practice since early 2008

  12. Fiducial marker insertion • Picture of Probe/Insertion

  13. $ 200

  14. Rectal Gas

  15. Loss Gas between AP and Lat

  16. Image “matched” to bone

  17. Matched to fiducials

  18. Results • Slightly more invasive • Very Feasible (even with prosthetic hip) • RTs enthusiastic, if 3mm or greater mis-match in any 1 plane, we correct in all 3 planes • Adds about 5 mins to 5 field prostate treatment (OTT in bunker from 9 to 14 mins)

  19. Where to next ? Fiducials • Now our standard treatment for intact prostate • Daily “on-line” seed matching allows tighter margins in all 3 planes hence • safe dose escalation to 78Gy with 3D-CRT • Same process crucial for IMRT 80Gy

  20. TRUS

  21. Setting up

  22. HDR brachytherapy

  23. HDR Brachytherapy

  24. RPA experience • First Case: January 2003 • 100th patient treated 28.11.2007 • Over 200 implants since technique introduced. • Team: ROs (Hruby, Patanjali), Urologists, Anaesthetics (JL), RTs, physics, nursing.

  25. Benefits of HDR • Conformality (and effects on normal tissues) • Radiobiologic advantage (low alpha/beta ratio of prostate cancer suggests hypofractionated treatment could improve response) • Shorter overall treatment time (patient convenience) • Recent systematic review of 3 modalities of dose escalation showed superiority of HDR as a boost (vs IMRT or seed brachy boost) – Pieters 2009

  26. Study Methods • Data collected prospectively (outcomes, toxicity, QOL) • Patients were considered for HDR boost if they had localised prostate cancer with intermediate or high risk features, AND were suitable for anaesthesia with a reasonable life expectancy (~10years)

  27. Radiation Technique • First 67 patients: 6.5Gy x 3# • Since then 2 separate implants for all patients • Dose escalation over last few yrs: 8.5 Gy x 2, 9 Gy x2, currently 9.5 Gy x2 • EBRT: 46Gy in 23# (prostate and seminal vesicles only)

  28. Failure • Biochemical failure defined by Phoenix definition (PSA nadir + 2) OR clinical failure, any of • Radiological evidence lymphatic or distant disease • LR on DRE, imaging or biopsy • Need for salvage treatment (LHRH)

  29. Patient Characteristics • Median age 68 (46-79) • Median PSA = 12 (3 – 43) • 31, 58, and 11 men had Clinical T1, 2 and 3 disease, respectively • GS 3+4 (36), 4+3 (42) • Intermediate risk: n=65 • High risk: n=35

  30. Androgen Ablation • 95 patients received neo-adjuvant and/or concomitant hormones • 80 for 6 months • 14 for 12 to 24 months • 1 patient 3 months only

  31. Results • Median F-up 49 months (17 to 85) • No data beyond 2 years for 3 patients • OS 99% (one patient died of an MI)

  32. Results continued • 15 patients failed – 7 biochemical and 8 clinical. • DFS rate intermediate risk = 90.8% high risk = 74.3% • To date, no patients have developed clinically apparent LR or metastatic disease.

  33. Acute toxicity • Acute effects: 69% of patients had grade 1-2 acute urinary toxicity; 54% GI effects (no grade 3 or 4) • Three patients had post op PEs; another patient was admitted to CCU with post op AF.

  34. Late toxicity • GU – rate of urethral stricture 8% (only one of these pts required more than one intervention) • GI – 8% mild (gd 1) toxicity, 3% grade 2, No grade 3 or 4. • Erectile function preservation rate 72% (53/75 patients who were potent at baseline had satisfactory EF post treatment)

  35. How do the results compare? • Comparable to large international series (the largest pooled analysis Galalae reported DFS of 69% and 88% for high and int risk respectively at 5yrs) • Toxicity also similar to that reported elsewhere (including Sullivan’s data on urethral strictures and most prostatectomy data)

  36. Discussion points • Young cohort, median age 68 • Good preservation of EF (age and microvasc disease recently proven to be risk factors in post RT ED) • PSA bounce – tends to occur in younger patients, probably reflecting testosterone recovery (6% in our cohort)

  37. Change in toxicity Profile • Shift in radiation related toxicity from rectum to urethra • MD Anderson gd 2+ rectal toxicity 26% in high dose arm (vs 13% in std arm) • Rates of urethral stricture comparable to other studies but still higher than seed brachy (up to 5.5%) EBRT (1-4%) and IMRT (3%)

  38. High risk patients • 74% DFS • However patients with more than one adverse feature (T3+, PSA>20, GS 8-10) all failed - Micro-mets ? • Individualisation of treatment – androgen deprivation and radiation volumes (? treating pelvic nodes in these pts)

  39. Evolution of Protocol • Shift from 3 fractions to 2 (out-patient tmt, eliminates problem of inter-fraction catheter displacement, ?better for patients – patient survey analysis pending) • Dose escalation (19Gy in 2#; ? 15Gy in 1#) • Fiducial markers – to quantify and account for intra-fraction catheter displacement (may be some time before we see if this translates into improved toxicity profile)

  40. Planning CT scout

  41. Pre treatment Film

More Related